Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fenofibrate
Drug ID BADD_D00873
Description Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]
Indications and Usage For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
Marketing Status Prescription; Discontinued
ATC Code C10AB05
DrugBank ID DB01039
KEGG ID D00565
MeSH ID D011345
PubChem ID 3339
TTD Drug ID D07XGR
NDC Product Code 68180-746; 0378-3065; 0115-0522; 46708-555; 27241-117; 71335-0891; 0115-1523; 68071-2587; 13672-020; 13668-439; 62332-361; 70934-567; 27241-116; 62332-555; 42291-292; 66869-137; 51407-094; 68543-3189; 0074-3189; 0378-3066; 16714-741; 46708-086; 31722-596; 70934-508; 68180-745; 65862-769; 71610-027; 16714-163; 50090-3044; 0378-7100; 0904-6810; 60505-3120; 51407-204; 42385-950; 66064-1006; 71335-1286; 71205-366; 50090-5401; 68180-130; 55111-395; 27241-120; 68071-2540; 71205-949; 62559-461; 69238-1261; 31722-595; 62559-305; 0378-7101; 50090-5796; 0115-0511; 43975-305; 50268-313; 42858-067; 68071-4692; 0904-7128; 68071-4992; 70518-3370; 62332-554; 68382-269; 43547-430; 35561-347; 63304-901; 27437-109; 16714-162; 17337-0410; 69238-1262; 62332-351; 68294-0001; 70518-2907; 43975-444; 50090-1275; 63304-449; 62332-539; 55111-349; 68180-231; 70518-2947; 51407-205; 59651-203; 59651-201; 62332-085; 62332-350; 63187-681; 69844-008; 42385-935; 68071-4983; 63304-444; 65862-768; 69097-458; 70966-0021; 68788-7579; 68180-360; 68382-270; 13668-438; 72189-172; 68071-3114; 68071-4310; 68462-581; 50090-4121; 71205-050; 50090-5854; 46708-351; 59349-0018; 62559-306; 50090-1274; 71335-0741; 69097-894; 60687-629; 42858-200; 69097-895; 35561-345; 68084-835; 46708-085; 60687-618; 68071-4358; 0074-3173; 51079-608; 50090-5327; 68788-7932; 63629-7213; 13668-440; 51407-091; 51407-092; 35561-346; 60760-411; 62332-360; 50090-3887; 50090-3842; 69238-1263; 51079-599; 68071-1601; 68084-827; 63629-2505; 42291-290; 70934-638; 70518-0700; 42858-660; 27241-118; 11014-0132; 71205-190; 68071-4264; 42385-951; 50268-309; 71335-1292; 71335-1756; 59651-202; 63629-1514; 68012-490; 0115-1522; 50090-4957; 49452-3101; 70756-214; 69844-013; 0378-4390; 16714-739; 68071-4320; 42385-936; 68084-329; 46708-857; 68071-5101; 63629-1099; 0904-7161; 68180-232; 63187-760; 46708-554; 50090-4698; 50090-3373; 46708-350; 27437-108; 46708-084; 0615-8270; 62332-086; 68788-8106; 17337-0019; 70934-223; 50090-2899; 68071-4182; 66869-147; 16714-740; 68180-131; 63187-640; 60760-318; 45802-315; 50268-312; 43353-898; 68084-328; 43598-910; 68543-3173; 70756-215; 51407-090; 72189-026; 62332-538; 17337-0430; 69367-257; 68012-495; 46708-361; 68462-582; 68682-495; 62332-084; 60760-660; 63304-443; 42291-289; 43598-909; 70518-2768; 43547-431; 27437-107; 0115-0533; 62559-460; 70934-224; 55700-876; 68071-4991; 11722-065; 50090-5244; 65977-0074; 70934-591; 63629-1100; 45802-132; 0378-4391; 69844-012; 69367-254; 42858-454; 68788-7662; 69367-269; 63629-1101; 27241-119; 71335-0872; 68180-389; 68071-4289; 60505-3121; 71335-2016; 50090-4031; 69367-270; 68180-363; 43353-272; 63187-940; 68071-2369; 69844-009; 69097-459; 50090-3904; 68180-362; 27437-110; 68084-635; 63304-448; 69097-896; 42858-134; 50090-2546; 58175-0348; 71335-1701; 69238-1260; 46708-360; 0115-5511; 63304-900; 0115-5522; 11014-0131; 68788-7578; 43353-001; 43975-306; 50090-5158; 51407-093; 68180-361; 69367-268; 53747-033; 68682-490; 68462-580; 70518-2349; 68071-4988; 68788-7816; 70518-1988; 68180-388
Synonyms Fenofibrate | Phenofibrate | Procetofene | Procetofen | Apo-Feno-Micro | Apo Feno Micro | Apo-Fenofibrate | Apo Fenofibrate | CiL | Controlip | durafenat | Fenobeta | Fenofanton | Fenofibrat AbZ | Fenofibrat AL | Fenofibrat AZU | AZU, Fenofibrat | Fenofibrat Heumann | Heumann, Fenofibrat | Fenofibrat Hexal | Hexal, Fenofibrat | Fenofibrat Stada | Stada, Fenofibrat | fenofibrat von ct | Fenofibrat-ratiopharm | Fenofibrat ratiopharm | Fénofibrate MSD | Gen-Fenofibrate | Gen Fenofibrate | LF-178 | LF 178 | LF178 | Lipanthyl | Lipantil | Fenofibrat FPh | Lipidil | Secalip | Supralip | Fénofibrate Debat | Debat, Fénofibrate | Lipidil-Ter | Lipidil Ter | Liparison | Livesan | Lofibra | MTW-Fenofibrat | MTW Fenofibrat | Novo-Fenofibrate | Novo Fenofibrate | Nu-Fenofibrate | Nu Fenofibrate | PMS-Fenofibrate Micro | PMS Fenofibrate Micro | Tricor | Normalip | Antara Micronized Procetofen | Micronized Procetofen, Antara | Procetofen, Antara Micronized
Chemical Information
Molecular Formula C20H21ClO4
CAS Registry Number 49562-28-9
SMILES CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Unintended pregnancy18.08.01.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.0010.000690%
Varicose vein24.10.04.001--Not Available
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Venous thrombosis24.01.01.0080.000173%Not Available
Ventricular extrasystoles02.03.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.0030.000259%
Visual acuity reduced17.17.01.011; 06.02.03.0010.000173%
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.0030.000949%
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.0050.000259%Not Available
Deep vein thrombosis24.01.02.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin burning sensation17.02.06.009; 23.03.03.0210.000345%Not Available
Vasodilation procedure25.03.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.0040.000345%
Hepatic enzyme increased13.03.01.0190.000259%Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Embolism24.01.01.009--
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages